Decrease clinical development costs and increase study quality using our global functional resources and flexible services, and get more value from your R&D spend.
-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Life Sciences Solutions
-
Healthcare Solutions
-
Medical Device and Diagnostic
-
U.S. Government
Life Sciences Solutions
Bringing together unparalleled healthcare data, advanced analytics, innovative technologies, and healthcare expertise to create intelligent connections that speed the development and commercialization of innovative medicines to improve patient lives.
Learn MoreLife Sciences Solutions
Healthcare Solutions
Helping you create a healthier world for all by harnessing innovation to improve access to and delivery of healthcare with sustainable models.
Learn MoreMedical Device and Diagnostic Solutions
Your world is unique – and quite different from pharma. In the U.S., decision-making has shifted from individual physicians to integrated networks--GPOs, IDNs and payers. These groups have heightened the focus on proving your solution’s value, demanding outcomes analyses and putting pressure on pricing.
Learn MoreMedical Device and Diagnostic Solutions
U.S. Government Solutions
For government agencies and organizations at every level—from federal or national to regional and local—Big Data can have a huge impact on public health.
Learn MoreU.S. Government Solutions
U.S. PROGRESS POINT
A curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREU.S. BLOGS
Get the latest insights on our life sciences, healthcare, and medical technology solutions in the United States. Follow our blog today!
LEARN MOREWhite Paper
Accelerating AI/ML Adoption in Biopharma
Dec 22, 2020
As companies realize the potential of Artificial Intelligence (AI) and Machine Learning (ML), applications in healthcare are expected to grow to nearly $8 billion by 2022. The biopharmaceutical industry is increasingly recognizing AI/ML’s potential to both improve decision making across R&D and commercialization, and to drive better outcomes for patients, physicians, and payers.
However, observers have yet to see meaningful and sustained realization of value from AI/ML in the biopharma industry. Further, most internal biopharma AI/ML initiatives remain fragmented and often separate from the main business.
In this white paper, IQVIA’s Data Science experts explore the reasons why AI/ML has had limited success in the biopharmaceutical industry to date, and contrast that examination with case studies spotlighting enterprises that successfully improved patient outcomes and streamlined internal operations through the use of AI/ML.
Download this white paper to discover how your biopharma organization can succeed in today’s increasingly complex and competitive environment by adopting AI/ML applications to enable:- Faster, more efficient clinical development
- More precise, tech-enabled commercial execution
- Better real world evidence to provide value
- Data-driven decision making to reduce risk
- More targeted therapies delivering better outcomes
Related solutions
Clinical Research & Development Solutions
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.